Moreover, platelet PD-L1 may increase the overall expression of PD-L1 in tumors after platelet adhesion to cancer cells [268], suggesting that adding an antiplatelet agent can improve the efficacy of anti-PD-L1 immunotherapy [269]. The gene discussed is CD274; the disease is cancer.